Time-limited pirtobrutinib, venetoclax, and obinutuzumab combination in first-line chronic lymphocytic leukemia

Nitin Jain(The University of Texas MD Anderson Cancer Center), William G. Wierda(The University of Texas MD Anderson Cancer Center), Himachandana Atluri(The University of Texas MD Anderson Cancer Center), Tapan M. Kadia(The University of Texas MD Anderson Cancer Center), Varsha Gandhi(The University of Texas Health Science Center at Houston), Dhruv Kumar(University of Kansas), Guillermo Montalban‐Bravo(The University of Texas MD Anderson Cancer Center), Kelly S. Chien, Cameron Noorbakhsh(The University of Texas MD Anderson Cancer Center), Alessandra Ferrajoli(The University of Texas MD Anderson Cancer Center), Álex Bataller(The University of Texas MD Anderson Cancer Center), Naval Daver(The University of Texas MD Anderson Cancer Center), Yesid Alvarado Valero(The University of Texas MD Anderson Cancer Center), Naveen Garg(The University of Texas MD Anderson Cancer Center), Deepa Sampath(The University of Texas MD Anderson Cancer Center), Jo Ishizawa, Musa Yılmaz(The University of Texas MD Anderson Cancer Center), Mahesh Swaminathan(The University of Texas MD Anderson Cancer Center), Koichi Takahashi(The University of Texas MD Anderson Cancer Center), Gautam Borthakur, Vanthana Bharathi(The University of Texas MD Anderson Cancer Center), Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Anna Evangelio(The University of Texas MD Anderson Cancer Center), Hyunsoo Hwang(The University of Texas MD Anderson Cancer Center), Naveen Pemmaraju(The University of Texas MD Anderson Cancer Center), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Wei Qiao(Johns Hopkins University), Elias Jabbour(The University of Texas MD Anderson Cancer Center), Michael J. Keating(The University of Texas MD Anderson Cancer Center), Jan A. Burger(The University of Texas MD Anderson Cancer Center), Wei‐Ying Jen(The University of Texas MD Anderson Cancer Center), Ana Ayala(The University of Texas MD Anderson Cancer Center), Fadi Haddad(The University of Texas MD Anderson Cancer Center)
Blood
November 3, 2025
10.1182/blood-2025-680
Cited by 3

Related Papers

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
|Blood|2017|1.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy
|Blood|1997|1.2k